Norway Karita Bekkemellem of Norwegian pharma association LMI highlights her work building up the profile of the industry in Norway, the market access and pricing challenges facing her member companies, and the country’s enduring potential as a leading clinical trial destination. Through diligent and long-term thinking, and building bridges and…
Europe Ole Olesen, executive director of the European Vaccine Initiative (EVI), shares the highlights of his first nine months in the job grappling with a global pandemic; the mission of EVI to support the development of non-commercially viable vaccines as well as to create a European vaccine infrastructure; as well as…
Norway Photo: Sofia Linden / Oslo Cancer Cluster Oncologist Jon Amund Kyte shares some of the groundbreaking immunotherapy research that he and his team is conducting at Oslo University Hospital. Kyte also explores how Norway can better develop its clinical footprint and what his hopes for the future of experimental cancer…
Norway Anette Margrethe Storstein MD PhD of the Norwegian Brain Council introduces the burden of neurodegenerative disease in Norway today, the ongoing impact of the country’s National Brain Plan, and Norway’s untapped potential in neuroscience R&D. Norway has unfulfilled innovation potential. There is a lot to be gained from an…
Norway Norway, more well-known internationally as an innovation hub for oil & gas and marine biology, is attempting to reverse the trend of reducing numbers of clinical trials and cultivate a domestic healthcare research industry. Drawing on the country’s comprehensive health registries, universal healthcare system, links with its Nordic neighbours, and…
Opinion Drs David Higgins and Marco F Schmidt highlight the gap that exists between the abundant discussions around technological innovation in healthcare and implementation and why pharma needs to develop its own proprietary approaches to crunching ‘wide data’. Data is the new oil, but biomedical data – despite its abundance…
Norway Ole Alexander Opdalshei introduces the role of the Norwegian Cancer Society within Norwegian cancer research, care services and information dissemination; how medical research charities are able to direct funding towards areas of cancer research missed by the private and public sectors; the burden of cancer within Norway; and the introduction…
Japan In 2020, Chugai Pharmaceutical Co. became Japan’s biggest drug company, driven by strong performance in recent years both from the company’s own drugs as well as those of parent company Roche. With Chugai now preparing for Phase III clinical trials for Roche’s Actemra for COVID-19, the company’s share price has…
Coronavirus Top global pharma executives involved in the development of COVID-19 vaccines have stated their commitment to not rushing the release of any potential vaccine without it passing through the full clinical trial process and proving to be safe and effective. Albert Bourla of Pfizer and Kenneth Frazier of Merck (MSD…
Norway Ketil Widerberg of the Oslo Cancer Cluster highlights how Norway’s excellence in electronic health records can help the country stake out a position as a significant cancer research destination. Widerberg also highlights the Cluster’s work to bridge seemingly disparate actors right across the oncology value chain, its collaboration with the…
Norway Anne Kjersti Fahlvik of the Research Council of Norway highlights the health sector’s increasing importance to the Nordic nation, the country’s existing strengths – including a robust public health system and early uptake of digital tools – and how Norway can draw on its excellence in the marine biology and…
Opinion Holmusk’s Nawal Roy outlines why a cure for Alzheimer’s Disease is the “Holy Grail” of medicine today, the reasons for so many biotech companies failing to develop effective treatments for the disease, and why a more holistic systems approach may be the key to future success. The ingenuity of…
See our Cookie Privacy Policy Here